Background {#Sec1}
==========

Since its introduction in the 1990s, the concept of fast-track surgery (FTS) has gained widespread acceptance and is now considered as a standard of care. FTS also referred to as enhanced recovery after surgery (ERAS) have been implemented in order to enhance recovery, reduce morbidity and mortality rates, and shorten hospital stay after major surgery. The aim of this novel approach to perioperative patient care is to decrease the perioperative stress response to the surgical trauma and thereby leading to a decrease in complication rates in surgery. These promising clinical results lead to the question of whether the concept of FTS also results in better-preserved immune function in the postoperative course. Some researchers believe that FTS also has positive effects on the human immune system, which may result in quicker recovery of postoperative immune function \[[@CR1]\]. Nevertheless, few clinical studies results have reported the impact of FTS on human immunity. Therefore, based on the hypothesis and present evidence of the benefits of FTS, we prospectively studied 276 patients underwent esophagectomy for esophageal cancer who either received FTS pathway or conventional pathway in the perioperative period. In addition to clinical outcome parameters, we analysed the effects of FTS on proinflammatory cytokine IL-6 and CRP levels as well as immunoglobulin and lymphocyte subgroups before surgery and on days 1, 3 and 5 after surgery.

Methods {#Sec2}
=======

Patients and procedures {#Sec3}
-----------------------

This study was conducted in the Department of Thoracic Surgery at Harbin Medical University Cancer Hospital from October 2013 to December 2014. Inclusion criteria included: age ≥18 and ≤75 years, American Society of Anesthesiologists (ASA) grade I/II, body mass index (BMI) 18.5--27.5 kg/m^2^, resectable esophageal cancer (page 36, NCCN Guidelines version 1.2013). However, we found in our previous clinical study involving patients with confounding factors that such factors might have a great impact on the results, such as immunological parameters for both controlled and observational groups. Therefore, some patients needed to be excluded from our study. The exclusion criteria of the study were as follows: patients with known immunological dysfunction (advanced liver disease (decompensated cirrhosis, portal hypertension or hepatocellular carcinoma), HIV infection, hepatitis C virus infection), pulmonary insufficiency (An acute or chronic condition marked by impaired pulmonary function, characterized by elevated carbon dioxide or decreased oxygen, or both), unresectable esophageal cancer (page 36, NCCN Guidelines version 1.2013), ASA III-IV, Karnofsky index less than 60, BMI less than 18.5 kg/m^2^, and age of 65--75 years with hypertension, diabetes, or vascular disease. Two hundred and seventy-six patients who were clinically diagnosed as having esophageal cancer were assigned to two groups comprising 138 patients each: FTS group and conventional group. Enrolled patients were randomly assigned to two groups using computer-generated random numbers. For approximately equal allocation to the two treatments, we took odd and even numbers to indicate treatments A (FTS group) and B (conventional group), respectively. The patients were admitted to different peri-operative care wards based on the computer-generated random numbers when they were admitted; specifically, 138 patients were randomized to traditional protocol wards and 138 to the FTS surgery wards.

Ten patients in the FTS group and 6 patients in the conventional group failed to undergo FTS and conventional pathway. Most of them did not undergo esophagectomy as expected. The final study population included 260 patients (Fig. [1](#Fig1){ref-type="fig"}). The relevant characteristics of patients and the types of surgery are listed in Table [1](#Tab1){ref-type="table"}. Gastroscope and barium meal of the upper gastrointestinal tract were systematically performed for tumors before operations. All patients underwent further work-up to assess the medical operability. This included evaluation of pulmonary and cardiac function, cervical and abdominal ultrasonography, chest computed tomography, and hematological examinations.Fig. 1Patient flow throughout the studyTable 1Characteristics of patients and their diagnosisCharacteristicsFTS group (*n* = 128)Conventional group (*n* =132)*P* valueMedian age56.43 ± 13.2855.72 ± 10.340.252Gender0.973 Male103 (80.5)106 (80.3) Female25 (19.5)26 (19.7)Weight (kg)67.53 ± 14.3766.45 ± 13.560.448BMI (kg/m^2^)22.53 ± 2.8522.89 ± 2.560.272Operating time (min)168.98 ± 30.62172.33 ± 24.670.438Blood loss (ml)302.54 ± 88.48312. 33 ± 76.730.727Operative incision0.749 One44 (34.4)48 (36.4) Two58 (45.3)62 (46.9) Three26 (20.3)22 (16.7)TNM0.773 I39 (30.5)36 (27.2) II71 (55.4)79 (59.8) III18 (14.1)17 (12.8) IV0 (0)0 (0)Pathology0.737Adenocarcinoma7 (5.5)8 (6.1)Squamous cell carcinoma116 (90.6)121 (91.6)Other5 (3.9)3 (2.3)Tumor location0.921 Upper esophagus12 (9.4)14 (10.6) Mid esophagus73 (57.0)76 (57.6) Distal esophagus43 (33.6)42 (31.8)Neoadjuvant therapy0.988 Yes68 (53.1)70 (53.0) No60 (46.9)62 (47.0)Neoadjuvant regimen0.923 Neoadjuvant chemoradiotherapy27 (39.7)25 (35.7) Neoadjuvant chemotherapy41 (60.3)45 (64.3) pCR after Neoadjuvant therapy15 (22.1)17 (24.2)0.776Surgical approach0.953 Conventional thoracotomy62 (48.4)66 (50.0) Hybrid VATS41 (32.0)42 (31.8) Pure VATS25 (19.6)24 (18.2)*Variables* were expressed as the mean ± SD*pCR* pathologic complete response rates

The FTS pathway used was developed by our cooperation team based on a previous protocol \[[@CR2]\]. The principles of the FTS and conventional pathways are described in Table [2](#Tab2){ref-type="table"}, and the principles of the postoperative FTS and conventional pathways are described in Table [3](#Tab3){ref-type="table"}. The study was approved by the Research Ethics Committee of Harbin Medical University, and written informed consent was obtained from all subjects.Table 2Principles of FTS pathway and conventional pathwayFTS pathwayConventional pathwayPreoperative educationPatients were educated systematically by the esophageal clinical nurse consultant;Patients were educated in the standard mannerDay before surgery DietLast drink 2 h and diet 6 h before operationLast drink and diet at midnight Fructose and protein loadingYesNoDay of surgery Nasogastric tubeNo routine use of nasogastric tubeRoutine use of nasogastric tube Pre-anesthetic medicationNoDiazepam 10 mg AnesthesiaGeneral anesthesia + Epidural anesthesia;General anesthesia; Maintaining normothermiaYesNo TransfusionAutologous blood transfusion or limit allogenic blood transfusionAllogenic blood transfusion Abdomen tubeNo routine use of drainsRoutine placement; Remove at POD3 Cervical tubeNo routine use of drainsRoutine placement; Remove at POD2 Early postoperative carePatient sent to floorPatient sent to ICU AnalgesiaEpidural PCAAnalgesia by morphine or vein PCA Enteral nutritionJejunostomy tube feedingNasojejunal tube feedingTable 3Daily guideline of postoperative care of patients with FTS pathway vs conventional pathwayDayFTS pathwayConventional pathwayPOD1Jejunostomy tube feeding 500 mL (starting at 20 mL/h)\
Early postoperative mobilization program (\>2 h out of bed)\
Physical therapy and nebulizers\
Remove urine catheter\
Head of bed put at 30°\
Supply albumin\
Chest tube to suction\
Promoted to lung recruitmentTotal parenteral nutrition\
Bed rest\
Gastrointestinal decompression\
Closed thoracic drainagePOD2Jejunostomy tube feeding 1000 mL (40 mL/h)\
Chest tube to suction\
Expand mobilization (\>4 h out of bed)\
Continue physical therapy and nebulizers\
Continue supply albuminNasojejunal tube feeding 500 mL (starting at 20 mL/h)\
Remove urine catheter\
With help, sit in the chair 2 times during the day for at least 30 min each time\
Gastrointestinal decompression\
Closed thoracic drainagePOD3Jejunostomy tube feeding 1500 mL (60--80 mL/h)\
Remove chest tube\
Remove epidural catheter\
Expand mobilization (\>6 h out of bed)\
Continue physical therapy and nebulizers\
Continue supply albuminNasojejunal tube feeding 1000 mL (40 mL/h)\
Sit in the chair 3 times for at least 30--60 min each time. With help, walk twice in the hallway.\
Do deep breathing exercise\
Remove nasogastric tube\
Closed thoracic drainagePOD4Gastrograffin opacification of upper gastrointestine\
If swallow shows no leak, advance patient to oral drink\
Jejunostomy tube feeding 1500 mL (60--80 mL/h)\
Continue physical therapy and nebulizers\
Education on aspiration precaution\
Education on chewing and swallowingNasojejunal tube feeding 1000 mL (40 mL/h)\
Sit in the chair 3 times today for at least 30--60 min each time. Walk the length of the hallway 3 times\
Continue to do breathing exercises\
Closed thoracic drainagePOD5Jejunostomy tube feeding 1500 mL (60--80 mL/h)\
Advance patient to a full liquid diet\
Continue aspiration precautions\
Continue physical therapy and nebulizersNasojejunal tube feeding 1500 mL (60--80 mL/h)\
Walk the length of the hallway 4--5 times. Sit in the chair 3 times today for at least 30--60 min\
Continue to do breathing exercisesPOD6Increase liquid diet\
Decrease jejunostomy tube feeding (500 ml or 1000 ml)\
Continue aspiration precautions\
Continue physical therapy and nebulizersNasojejunal tube feeding 1500 mL (60--80 mL/h)\
Remove chest tube\
Walk the length of the hallway 4--5 times. Sit in the chair 3 times today for at least 30--60 min\
Continue to do breathing exercisesPOD7Remove jejunostomy tube\
Full liquid diet\
Discharge home on soft diet and liquid diet\
Continue aspiration precautionsGastrograffin opacification of upper gastrointestine\
If swallow shows no leak, advance patient to oral drink\
Nasojejunal tube feeding 1500 mL (60--80 mL/h)\
Expand mobilization (\>4 h out of bed)\
Continue to do breathing exercisesPOD8Increase liquid diet\
Decrease jejunostomy tube feeding (500 ml or 1000 ml)\
Expand mobilization (\>6 h out of bed)\
Continue to do breathing exercisesPOD9Remove nasojejunal tube\
Full liquid diet\
Expand mobilization (\>6 h out of bed)\
Continue to do breathing exercisesPOD10-11Soft diet and liquid diet\
Nearly out of bed\
Observe whether there is delayed anastomotic leakagePOD12Discharge home on soft diet and liquid diet

Clinical parameters {#Sec4}
-------------------

The post-operative hospital stay defined as time spent in the hospital from the day of operation to the day of hospital discharge, including readmission stay within 30 days postoperatively. The complications were defined as atrial arrhythmia, anastomotic leak, ileus, pneumonia, ARDS and incision infection. Readmission rate was also recorded. Pain while coughing, staying in bed or during exercise was judged by the patients three times daily until day 5 after surgery using the numeric rating scale (0, no pain to 10, maximum pain). The perioperative hospital charges included surgery, anesthesia, drugs, auxiliary examination (including laboratory and radiology), and care costs, but didn't include neoadjuvant therapy costs.

Protocol for esophageal cancer {#Sec5}
------------------------------

The diagnostic and therapeutic protocols for patients with esophageal cancer at the authors' institution is based on NCCN Guidelines version 1.2013 (page 36--37). Since the R0-resection rate and long-term outcome of patients with T3/T4 tumors is poor with primary resection, multimodal therapeutic concepts with preoperative chemotherapy or combined radiochemotherapy or both are employed in these patients.

Pro-inflammatory parameters {#Sec6}
---------------------------

Peripheral venous blood samples were collected in serum collection tubes (Kabe) and were subsequently centrifuged at 300 × g for 15 min at 4 °C and serum samples were subsequently stored at −80 °C until assayed for IL-6.

Circulating serum IL-6 levels were determined using sandwich enzyme-linked immunosorbent assay (Biosource, Nivelles, Belgium) as described by the manufacturer. CRP was measured with the immunoturbidimetric method (Olympus, Hamburg, Germany).

Immunological parameters {#Sec7}
------------------------

Blood samples were taken on the day before surgery as well as on days 1, 3 and 5 after surgery. All blood samples were taken from peripheral veins at 6 a.m., before breakfast. The humoral immunologic factors tested in our study included serum globulin, immunoglobulin G (IgG), immunoglobulin M (IgM), immunoglobulin A (IgA).

Lymphocyte subpopulation parameters {#Sec8}
-----------------------------------

Lymphocyte subpopulations (CD3, CD4, and CD8 lymphocytes, and the CD4/CD8 ratio) were determined by flow cytometry (Becton Dickinson, San Jose, CA, USA). The monoclonal antibodies used for immunophenotyping were purchased from Becton Dickinson and conjugated to the fluorochromes, fluorescein isothiocyanate or phycoerythrin. The fluorescence was measured using a FACScalibur (Becton Dickinson) within 60 min of processing of the samples. Fluorescent-activated cell sorting analysis was carried out on a FACScalibur flow cytometer. A minimum of 10,000 cells were measured for each determination.

Discharge and follow-up {#Sec9}
-----------------------

Patients were discharged only if they could tolerate a semiliquid or soft diet and walk freely in the ward. Data were collected prospectively and retrieved from our database. Complete follow-up was available until 1 month after surgery.

Statistical analysis {#Sec10}
--------------------

Outcome data were analyzed with the use of repeat measurement ANOVA for continuous variables and chi-square test or Fisher's exact test for categorical variables. All analyses were performed with the statistical package SPSS (version 13.0; Chicago, IL). A *P* value of \<0.05 was considered significant.

Results {#Sec11}
=======

In all, 260 patients finished the study, including 128 patients in the FTS group and 132 patients in the conventional group. Ten patients were excluded from the FTS group and six patients from the conventional group (Fig. [1](#Fig1){ref-type="fig"}). No significant differences were observed in sex, age, weight, BMI, operating time, blood loss, operative incision, tumor TNM stage, tumor pathology, tumor location and neoadjuvant therapy between the two groups (Table [1](#Tab1){ref-type="table"}).

Clinical parameters {#Sec12}
-------------------

Postoperative hospital stay in patients randomized to the FTS group was significantly shorter than in the conventional group (*P* \< 0.05). The mean charge for perioperative hospital stay was 35823.62 ± 3598.81 renminbi (RMB) for the FTS group, which was significantly less than the cost of 41032.73 ± 4013.32 RMB for the conventional group (*P* \<0.05). Incision pain according to the Numeric Rating Scale was lower in patients of the FTS group than in those of the conventional group (*P* \<0.05). And we had compared the degree of pain among three different surgical approaches: pure video-assisted thoracic surgery (VATS), hybrid VATS, and conventional thoracotomy. In the early postoperative period, pure VATS was shown to be the least painful of the three surgical approaches. No statistically significant differences were detected in postoperative complications between the two groups (*P* \< 0.05). There was, however, a trend toward more postoperative complications (9.8 %) in patients undergoing conventional pathway (Table [4](#Tab4){ref-type="table"}). According to Clavien-Dindo classification, 11 (8.6 %) patients in FTS group and 16 (12.1 %) patients in conventional group suffered stageI, II and III complications respectively. Two patient in FTS group and three patient in the conventional group was diagnosed atrial arrhythmia by an ECG recording (I). Two patient in FTS group and two patient in the conventional group showed incision infection (I). One patient in the conventional group developed postoperative paralytic ileus and required reinsertion of a nasogastric tube, and this was resolved by restricting intake and parenteral nutrition (II). Three patients in FTS group and four patients in the conventional group had pneumonia and this was resolved by physical therapy and antibiotic treatment (II). Anastomotic leak occurred in two patient in FTS group and three patients in the conventional group, and this was resolved by endoscopic treatment (III). Two patients in FTS group and three patients in the conventional group had ARDS and were treated with mechanical ventilation in the Intensive Care Unit (IV).Table 4Comparison of outcome of two groupOutcomesFTS group (*n* = 128)Conventional group (*n* =132)*P* valuePostoperative hospital stay (d)7.62 ± 1.3812.56 ± 1.920.000Hospitalization expenditure (RMB)35823.62 ± 3598.8141032.73 ± 4013.320.000Incision pain scale (NRS)4.72 ± 1.947.66 ± 1.590.000Morbidity11 (8.6)16 (12.1)0.351 Atrial arrhythmia23 Ileus01 Pneumonia34Anastomotic leak23 Incision infection22ARDS23Mortality2 (1.6)2 (1.5)1.00030-day readmission rate3 (2.3)3 (2.3)1.000*Variables* were expressed as the mean ± SDThe Numeric Rating Scale (NRS) is an 11--point (0--10) scale for patient self-reporting of pain. It is for adults and children 10 years old or older*RMB* Ren Min Bi or China Yuan

Pro-inflammatory parameters {#Sec13}
---------------------------

On PODs 1 and 3, statistically significant differences were found in levels of IL-6 and CRP with the FTS group having lower levels than in the conventional group (*P* \<0.05). On POD 7, the level of CRP was lower in the FTS group than that in the conventional group (*P* \<0.05) (Table [5](#Tab5){ref-type="table"}).Table 5Comparison of inflammatory markers in two groupsFactor and timeFTS group (*n* = 128)Conventional group (*n* = 132)*P* valueIL-6 (ng/L) Before surgery53.83 ± 21.6655.73 ± 20.370.585 POD1121.74 ± 22.57138.77 ± 21.53\*0.000 POD3142.37 ± 25.09154.90 ± 24.33\*0.035 POD7116.70 ± 22.39122.79 ± 25.640.412CRP (μg/L) Before surgery4.97 ± 1.334.85 ± 1.431.000 POD165.57 ± 13.3774.61 ± 14.71\*0.034 POD3136.79 ± 23.34155.38 ± 28.75\*0.012 POD751.83 ± 17.6662.36 ± 18.37\*0.042*Variables* were expressed as the mean ± SD\* *P* \<0.05

Immunological parameters {#Sec14}
------------------------

There were no significant differences in the post-operativelevel and pre-operative level of IgM and CD8 between the two groups. On PODs 1 and 3, statistically significant differences were found in the levels of IgG, IgA, CD3, CD4 and CD4/CD8 ratio with the FTS group having higher levels than the conventional group (all *P* \<0.05). On POD 3, the level of serum globulin was higher in the FTS group than that in the conventional group (*P* \<0.05) (Table [6](#Tab6){ref-type="table"}). We performed subgroup analysis based on neoadjuvant or not, as well as MIE (Minimally invasive esophagectomy) or not for avoiding bias, and we came to similar conclusions after data analysis (Tables [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}, [9](#Tab9){ref-type="table"} and [10](#Tab10){ref-type="table"}).Table 6Comparison of immunologic factors in two groupsFactor and timeFTS group (*n* = 128)Conventional group (*n* = 132)*P* valueGlobulin (g/l) Before surgery28.37 ± 3.9327.32 ± 4.330.943 POD122.74 ± 3.9322.39 ± 3.821.000 POD325.66 ± 2.9422.21 ± 2.99\*0.038 POD729.95 ± 3.8527.97 ± 4.410.537IgG (g/l) Before surgery14.38 ± 2.7815.33 ± 3.790.573 POD18.97 ± 1.796.11 ± 1.38\*0.033 POD311.02 ± 3.538.17 ± 2.94\*0.002 POD714.53 ± 3.8113.02 ± 3.730.741IgA (g/l) Before surgery2.79 ± 0.522.98 ± 0.350.757 POD11.81 ± 0.431.65 ± 0.17\*0.012 POD32.08 ± 0.541.76 ± 0.47\*0.003 POD72.58 ± 0.472.62 ± 0.390.637IgM (g/l) Before surgery1.21 ± 0.351.24 ± 0.441.000 POD10.82 ± 0.390.89 ± 0.430.964 POD30.75 ± 0.220.77 ± 0.310.543 POD71.18 ± 0.591.23 ± 0.480.424CD3 Before surgery55.99 ± 2.7257.83 ± 2.640.813 POD149.92 ± 2.7546.01 ± 2.83\*0.042 POD351.83 ± 2.4248.02 ± 2.51\*0.019 POD755.05 ± 2.6953.83 ± 2.710.737CD4 Before surgery45.58 ± 3.9244.97 ± 4.320.958 POD133.26 ± 4.7230.37 ± 5.21\*0.039 POD339.39 ± 4.8134.34 ± 5.72\*0.012 POD743.76 ± 4.3842.87 ± 3.980.887CD8 Before surgery26.73 ± 4.8526.08 ± 3.971.000 POD123.72 ± 4.3324.42 ± 4.740.958 POD323.76 ± 3.8322.73 ± 4.650.832 POD728.73 ± 4.3827.62 ± 3.830.732CD4/CD8 Before surgery1.53 ± 0.331.48 ± 0.420.739 POD11.45 ± 0.311.22 ± 0.45\*0.042 POD31.52 ± 0.451.39 ± 0.30\*0.023 POD71.58 ± 0.321.53 ± 0.540.865*Variables* were expressed as the mean ± SD\* *P* \<0.05Table 7Comparison of inflammatory markers and immunologic factors in two groups without neoadjuvantFactor and timeFTS group (*n* = 60)Conventional group (*n* = 62)*P* valueIL-6 (ng/L) Before surgery52.13 ± 25.5454.67 ± 22.360.651 POD1123.43 ± 20.73139.26 ± 22.92\*0.007 POD3144.05 ± 26.39156.25 ± 25.38\*0.032 POD7117.23 ± 21.29123.36 ± 25.560.321CRP (mg/L) Before surgery4.92 ± 1.534.83 ± 1.720.953 POD166.37 ± 12.9375.52 ± 14.88\*0.023 POD3138.84 ± 22.04156.58 ± 29.21\*0.019 POD753.84 ± 16.9564.06 ± 16.74\*0.031Globulin (g/l) Before surgery28.82 ± 3.9327.97 ± 5.210.643 POD122.25 ± 3.8321.09 ± 3.900.231 POD325.72 ± 3.0822.68 ± 2.89\*0.026 POD728.56 ± 2.2527.74 ± 4.040.447IgG (g/l) Before surgery15.82 ± 2.9814.18 ± 3.690.585 POD18.87 ± 1.656.32 ± 1.19\*0.025 POD310.88 ± 3.377.94 ± 2.87\*0.000 POD714.51 ± 2.8313.97 ± 3.630.231IgA (g/l) Before surgery2.76 ± 0.332.85 ± 0.270.654 POD11.71 ± 0.541.45 ± 0.14\*0.013 POD31.98 ± 0.471.67 ± 0.52\*0.002 POD72.53 ± 0.332.42 ± 0.380.585IgM (g/l) Before surgery1.24 ± 0.331.19 ± 0.460.841 POD10.85 ± 0.490.81 ± 0.320.432 POD30.77 ± 0.170.71 ± 0.260.233 POD71.15 ± 0.531.21 ± 0.500.190CD3+ Before surgery57.92 ± 2.6358.23 ± 2.480.764 POD148.87 ± 2.5146.13 ± 2.78\*0.047 POD351.17 ± 2.2048.19 ± 2.31\*0.013 POD755.59 ± 2.2853.07 ± 2.840.230CD4+ Before surgery44.28 ± 3.4844.73 ± 4.520.864 POD134.95 ± 4.7231.07 ± 5.09\*0.020 POD338.52 ± 3.6134.54 ± 5.22\*0.016 POD743.38 ± 5.8642.48 ± 3.840.382CD4+/CD8+ Before surgery1.64 ± 0.321.55 ± 0.490.872 POD11.43 ± 0.211.20 ± 0.51\*0.036 POD31.54 ± 0.551.41 ± 0.34\*0.018 POD71.57 ± 0.241.51 ± 0.280.341*Variables* were expressed as the median ± quartile\* *P* \<0.05Table 8Comparison of inflammatory markers and immunologic factors in two groups with neoadjuvantFactor and timeFTS group (*n* = 68)Conventional group (*n* = 70)*P* valueIL-6 (ng/L) Before surgery50.57 ± 21.4551.42 ± 19.830.979 POD1119.54 ± 18.62131.42 ± 21.58\*0.004 POD3138.42 ± 22.73150.48 ± 21.97\*0.043 POD7112.52 ± 19.43116.43 ± 22.570.573CRP (mg/L) Before surgery4.53 ± 1.244.45 ± 1.290.942 POD161.32 ± 13.7770.52 ± 11.56\*0.032 POD3132.73 ± 21.56150.49 ± 25.72\*0.013 POD749.78 ± 15.8460.43 ± 16.38\*0.035Globulin (g/l) Before surgery25.67 ± 3.3425.82 ± 4.391.000 POD121.43 ± 3.6320.21 ± 3.450.760 POD324.76 ± 3.8221.64 ± 2.94\*0.023 POD725.73 ± 3.3525.87 ± 4.090.848IgG (g/l) Before surgery13.76 ± 3.1313.62 ± 3.420.858 POD17.42 ± 1.425.23 ± 1.35\*0.031 POD39.42 ± 3.536.44 ± 2.95\*0.001 POD712.56 ± 2.6711.94 ± 3.830.656IgA (g/l) Before surgery2.19 ± 0.292.21 ± 0.250.769 POD11.61 ± 0.371.34 ± 0.25\*0.017 POD31.85 ± 0.421.51 ± 0.51\*0.004 POD72.04 ± 0.372.15 ± 0.420.753IgM (g/l) Before surgery1.14 ± 0.311.11 ± 0.410.893 POD10.71 ± 0.390.72 ± 0.330.957 POD30.67 ± 0.220.64 ± 0.320.873 POD71.09 ± 0.431.10 ± 0.420.673CD3+ Before surgery55.62 ± 2.4356.82 ± 2.580.875 POD146.73 ± 2.5244.09 ± 2.03\*0.043 POD349.82 ± 2.4346.17 ± 2.35\*0.033 POD753.85 ± 2.0554.04 ± 2.730.482CD4+ Before surgery42.43 ± 3.5742.48 ± 4.920.803 POD132.52 ± 4.1329.12 ± 5.02\*0.025 POD335.32 ± 3.9032.55 ± 5.02\*0.013 POD741.42 ± 5.2440.98 ± 4.270.484CD4+/CD8+ Before surgery1.52 ± 0.411.55 ± 0.450.842 POD11.33 ± 0.361.11 ± 0.41\*0.027 POD31.47 ± 0.561.32 ± 0.37\*0.025 POD71.50 ± 0.361.52 ± 0.290.562*Variables* were expressed as the median ± quartile\* *P* \<0.05Table 9Comparison of inflammatory markers and immunologic factors in two groups without MIEFactor and timeFTS group (*n* = 63)Conventional group (*n* = 65)*P* valueIL-6 (ng/L) Before surgery53.26 ± 24.1853.58 ± 23.140.842 POD1123.73 ± 22.69139.42 ± 24.78\*0.006 POD3143.31 ± 25.42155.79 ± 24.42\*0.043 POD7117.73 ± 22.45123.57 ± 23.840.571CRP (mg/L) Before surgery4.94 ± 1.484.86 ± 1.320.943 POD166.42 ± 13.7375.75 ± 13.57\*0.032 POD3137.76 ± 24.73156.79 ± 27.42\*0.015 POD752.75 ± 15.7963.73 ± 15.2\*0.042Globulin (g/l) Before surgery27.82 ± 3.5928.71 ± 5.330.875 POD121.63 ± 3.5421.79 ± 3.820.941 POD325.59 ± 3.1422.79 ± 2.98\*0.043 POD728.73 ± 3.0827.95 ± 4.240.545IgG (g/l) Before surgery14.59 ± 3.2813.97 ± 3.820.833 POD18.93 ± 1.596.47 ± 1.25\*0.034 POD310.51 ± 3.567.82 ± 2.96\*0.000 POD713.75 ± 2.9713.66 ± 3.320.741IgA (g/l) Before surgery2.65 ± 0.412.75 ± 0.321.000 POD11.78 ± 0.491.41 ± 0.25\*0.009 POD31.94 ± 0.461.65 ± 0.43\*0.004 POD72.43 ± 0.352.49 ± 0.410.842IgM (g/l) Before surgery1.26 ± 0.411.21 ± 0.330.892 POD10.83 ± 0.380.85 ± 0.360.731 POD30.72 ± 0.190.71 ± 0.221.000 POD71.19 ± 0.491.24 ± 0.420.766CD3+ Before surgery58.03 ± 2.5257.43 ± 2.670.852 POD148.93 ± 2.4745.89 ± 2.49\*0.048 POD351.67 ± 2.3347.87 ± 2.52\*0.011 POD754.68 ± 2.3253.25 ± 2.930.473CD4+ Before surgery44.37 ± 3.5244.52 ± 4.310.768 POD136.43 ± 4.2832.66 ± 5.14\*0.028 POD339.13 ± 4.5233.95 ± 5.38\*0.004 POD742.57 ± 4.3842.64 ± 3.951.000CD4+/CD8+ Before surgery1.59 ± 0.411.54 ± 0.430.892 POD11.47 ± 0.231.22 ± 0.41\*0.032 POD31.51 ± 0.451.40 ± 0.51\*0.012 POD71.54 ± 0.291.57 ± 0.210.842*Variables* were expressed as the median ± quartile\* *P* \<0.05Table 10Comparison of inflammatory markers and immunologic factors in two groups with MIEFactor and timeFTS group (*n* = 65)Conventional group (*n* = 67)*P* valueIL-6 (ng/L) Before surgery52.33 ± 24.3753.42 ± 22.730.764 POD1119.34 ± 21.57134.42 ± 22.53\*0.005 POD3140.05 ± 25.63151.67 ± 24.52\*0.035 POD7113.72 ± 22.42117.66 ± 25.740.152CRP (mg/L) Before surgery4.62 ± 1.634.53 ± 1.570.842 POD162.42 ± 13.8371.42 ± 14.32\*0.027 POD3134.73 ± 22.57153.82 ± 25.62\*0.017 POD750.46 ± 15.7361.43 ± 15.66\*0.012Globulin (g/l) Before surgery27.72 ± 3.5527.58 ± 5.140.942 POD123.57 ± 3.7322.64 ± 3.730.543 POD325.42 ± 3.9523.31 ± 3.52\*0.021 POD728.04 ± 2.7627.87 ± 4.130.735IgG (g/l) Before surgery14.63 ± 2.5714.03 ± 3.10.872 POD19.43 ± 1.257.62 ± 1.17\*0.028 POD311.82 ± 3.528.73 ± 2.94\*0.002 POD714.42 ± 2.7613.52 ± 3.330.542IgA (g/l) Before surgery2.57 ± 0.312.77 ± 0.290.767 POD11.83 ± 0.411.54 ± 0.22\*0.015 POD31.99 ± 0.351.69 ± 0.42\*0.000 POD72.55 ± 0.322.52 ± 0.320.652IgM (g/l) Before surgery1.28 ± 0.311.21 ± 0.360.853 POD10.94 ± 0.430.92 ± 0.350.482 POD30.87 ± 0.210.81 ± 0.320.353 POD71.25 ± 0.461.22 ± 0.520.320CD3+ Before surgery57.43 ± 2.8258.12 ± 2.730.873 POD149.69 ± 2.4347.02 ± 2.57\*0.044 POD353.38 ± 2.5749.93 ± 2.65\*0.017 POD756.73 ± 2.5256.48 ± 2.491.000CD4+ Before surgery44.52 ± 3.4644.37 ± 4.411.000 POD135.87 ± 4.1532.35 ± 4.89\*0.022 POD339.98 ± 3.7335.43 ± 4.64\*0.013 POD744.73 ± 5.0243.76 ± 3.920.859CD4+/CD8+ Before surgery1.58 ± 0.301.52 ± 0.420.973 POD11.49 ± 0.241.26 ± 0.43\*0.031 POD31.64 ± 0.451.45 ± 0.28\*0.015 POD71.56 ± 0.321.50 ± 0.370.458*Variables* were expressed as the median ± quartile\**P* \<0.05

Discussion {#Sec15}
==========

Recent clinical data indicate that FTS leads to shorter postoperative length of hospital stay, faster recovery of gastrointestinal function as well as reduced morbidity and mortality rates \[[@CR1], [@CR3], [@CR4]\]. To date, no study has focused on the effects of FTS on immune function after esophagectomy for esophageal cancer. This study was initiated to determine whether FTS results in improved clinical and immunological outcome of patients undergoing esophagectomy for esophageal cancer.

The normal inflammatory response, more commonly known as the stress response, was first described by Sir David Cuthbertson \[[@CR5]\]. Despite variability in the intensity of the stress response, the timeline of events remains remarkably similar, with few exceptions. Virtually all mediators of inflammation and metabolism peak about postinjury day 2 and then return to baseline levels by postinjury days 6--7. The inflammatory response may obviously be important for wound healing and resistance to infection, but on the other hand may have undesirable effects by enhancing pain and leading to fatigue and sleep disturbances \[[@CR6]\]. Inflammation is triggered when innate immune cells detect infection or tissue injury. We found most of immune markers decreased under condition of the increase of pro-inflammatory cytokines. This research into the mechanisms that immune impact may provide a novel therapeutic pathway that can alter the nature and time course of the stress response.

Perioperative intervention improvements that might be contributed to the immunologic protection, including taking a carbohydrate rich drink before surgery, early enteral nutrition and epidural analgesia. Before surgery, patients often already have poor nutritional status and low immune function. For patients with esophageal cancer, their nutritional status will be worsened after surgeries, along with the decrease of the cellular and humoral immunity \[[@CR7]\]. Some studies indicated that taking a carbohydraterich drink before surgery could reduce the endocrine catabolic response and improve insulin resistance, improving surgical results and hastening recovery \[[@CR8], [@CR9]\]. Gut is regarded as a central organ after surgical stress; also, among the intestinal mucosal barrier functions, immune barrier plays an important role. the functions of small intestine often return normal 6--12 h after the surgery, which supports the early application of enteral nutrition (EN) after surgery \[[@CR10]\]. Clinically, EN is applied to facilitate the improvement of nutritional status, restoration of immune function, and protection of intestinal mucosal barrier after the surgeries. A recent study verified that partial EN support during perioperation will not only improve the postoperative nutritional status and immune function, but also moderate the inflammatory response of gastric cancer patients after operative trauma \[[@CR11]\]. Beier-Holgersen et al. \[[@CR12]\] proved early postoperative enteral nutrition had an important influence on immediate unspecific cellular immunity and had an activating effect on specific cellular immunity. In our current randomized and controlled study, we provided EN with postoperative patients in the FTS group on POD1 and in the conventional group on POD2. The immune globulins (IgA and IgG) and T lymphocyte subsets (CD3, CD4 and CD4/CD8) at POD1, 3 were higher in the FTS group than them in the conventional group, showing a fast recovery of immunity. We hypothesized that the fast recovery of immunity might be ascribed to the fact that the earlier activation of the immune system by earlier EN after surgery.

It has been verified that nociception and proinflammatory cytokines play a mutual up-regulatory role \[[@CR13]\]. Therefore, pain management may influence the immune response in the postoperative period. It has been reported that the alterations in lymphocyte subsets and the increase in white cell counts induced by surgery and general anesthesia can be prevented by epidural analgesia \[[@CR14], [@CR15]\]. Furthermore, Beilin et al. \[[@CR16]\] reported that patients treated with patient-controlled analgesia (PCA) exhibited attenuated proinflammatory cytokine response in the postoperative period. Also Khaled et al. \[[@CR17]\] showed that thoracic epidural analgesia reduced the systemic pro-inflammatory response and provided optimal post-operative pain relief. In major surgery, however, the effect of epidural anesthesia and analgesia on attenuation of the stress response and preservation of immune function is controversial.

The difference in immune function between the two groups was also statistically significant. There are several factors that may account for these differences. The duration of surgery and anesthesia, extent of tissue injury, and blood loss are usually great in patients undergoing esophagectomy. Blood transfusion is another factor in inducing immunosuppression. There is increasing evidence to suggest that perioperative blood transfusion may have an immunomodulatory effect. A previous study \[[@CR18]\] of patients undergoing esophageal resection for carcinoma has demonstrated a significantly worse prognosis for those receiving a blood transfusion independent of disease stage or the presence of major complications. It has been suggested that the immunosuppression induced by transfusion results from both an early unspecific immunosuppression mediated by monocytes and a later phase induced from increased suppressor T cell activity. Blood transfusion has been shown to lower the CD4 to CD8 ratio \[[@CR19]\]. In addition, prostaglandin E2 levels are increased after transfusion \[[@CR20]\]. This may result in a direct inhibition of interleukin-2 production from CD4 cells with subsequent effect, as interleukin-2 is obligatory for natural killer cell activity. In addition, it shows that transfusion of more than 3 units of blood can adversely affect survival \[[@CR21]\]. Therefore, every effort should be made to limit the amount of blood transfused to the minimum requirement.

Cellular immunity is mediated by lymphocytes and transferred by the cells of immunized people. Humoral immunity is mediated by antibodies and transferred by the sera of immunized people. Impairment of cellular and humoral immune system may lead to infections secondary to surgery, progression of malign tumors, and emergence of opportunistic infections. IL-6 is known to be a major mediator of the acute-phase response and plasma levels of IL-6 are reportedly related to the severity of surgical trauma \[[@CR22]\]. It can stimulate the liver to synthesize C-reactive protein (CRP), enhance inflammatory reaction by promoting B cell differentiation and antibody formation, and assist the T cells to produce the expressions of IL-2 and its receptor \[[@CR23]\]. In our current study, no significant difference was found in both groups of immunological parameters before surgery and POD7. At PODs 1 and 3, the immune function indicators decreased in both groups. In the FTS group, the immune globulins (IgA and IgG) and T lymphocyte subsets (CD3, CD4 and CD4/CD8) were significantly higher than those in the conventional group (*P* \< 0.05), whereas IL-6 and CRP were significantly lower (*P* \< 0.05). Therefore, the FTS is helpful to improve the immune function in patients undergoing esophagectomy for esophageal cancer.

Another powerful technique to reduce inflammatory responses is decreasing the wound size by minimal invasive surgery. It is well established that this may reduce pain and inflammatory responses especially proinflammatory cytokines (IL-6 etc.) \[[@CR24]\]. Inflammatory responses contribute to pain, fatigue and organ dysfunction. Minimally invasive surgery also reduces the inflammatory response, although the contribution that this plays in the context of fast-track programmes in esophageal surgery is difficult to interpret. We found that the immune function of patients is mildly affected by minimally invasive surgery. No significant differences were observed in immune function between the minimally invasive surgery group and the open surgery group. Of interest, a recent randomized blinded study by Basse et al. showed that FTS leads to similar clinical and functional results in patients undergoing open as well as laparoscopic colorectal resections \[[@CR25]\]. This indicates that the clinical advantages of laparoscopic surgery may be of only minor importance for postoperative recovery if the concept of FTS surgery is used for patients after major surgery. Minimal invasive surgery on a procedure-specific basis therefore represent a major opportunity to further enhance recovery and reduce morbidity in the future, especially when combined with other aspects of the fast-track methodology.

Our results did not detect statistically significant changes in serum IgM and CD8 lymphocytes between the two groups. However, this does not mean that FTS has no effects on these factors, which may be explained by the time that blood samples were taken or the relatively small number of cases in our trial. The above factors may be differences between the two groups if we increase the time that blood samples were taken, or increase the amount of cases.

Only a small proportion of patients in our study underwent Pure VATS surgery. We have not enough evidence to demonstrate the effect of minimally invasive surgery on immunity. Therefore, the changes of immune indexes by laparoscopic and thoracoscopic surgery needs to be investigated in further studies.

Conclusions {#Sec16}
===========

The beneficial clinical effects of FTS reported here support the findings of other groups and our data on perioperative immunity suggest that better-preserved cellular and humoral immunity may contribute to the improvement of postoperative results in fast-track patients. The precise mechanism of changes in immunological parameters in FTS needs further study.
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